---
pagetitle: "ICI resistance"
format:
  revealjs:
    transition: fade
    theme: [default, catppuccin.scss]
    cap-location: bottom
    appearance:
      appearparents: true
  pptx:
    output-file: sws_gr_2024.pptx
bibliography: /home/martin/Documents/PhD/sws_gr/references.bib
revealjs-plugins:
  - appearance
  - fontawesome
---

## {#title data-menu-title="Title" background-image="img/macchiato-bg.png"}

[Primary Resistance Paradox: When Immune Checkpoint Inhibitors meet their match]{.title} [PhD candidate: Martin Hong <br> Supervisors: Prof Tara Roberts & Prof Wei Chua <br> SWS Research Grand Rounds <br> 29 May 2024]{.subtitle}

## Overview {data-autoappear=true}

* Background
* Significance of Research
* Prospective biomarkers

# Background

## Role of immune checkpoints 

::::{.columns}

:::{.column width="40%"}

:::{.fragment fragment-index=1 .fade-left}
* Maintain tolerance to self {{< fa arrow-right >}} preventing auto-immunity
:::

:::{.fragment fragment-index=2 .fade-left}
* Hanahan & Weinberg identified immune evasion as a hallmark of cancer
:::

:::{.fragment fragment-index=4 .fade-left}
* Immune checkpoints, e.g. cytotoxic T-lymphocyte associated protein 4 (CTLA4) and programmed cell death protein 1 (PD-1), inhibits activation of lymphocytes
:::

:::

:::{.column width="60%"}

::: {.r-stack}
::: {.fragment fragment-index=3 .fade-in-then-out .absolute width="510" height="347" top=150 right=-30}
![](./img/h_w_2011.jpg)^[@hanahanHallmarksCancerNext2011]
:::
::: {.fragment fragment-index=5 .fade-in-then-out .absolute width="200" height="520" top=100 right=100}
![](./img/t_act.png)^[Created with BioRender.com]
:::
::: {.fragment fragment-index=6 .fade-in-then-out .absolute width="200" height="520" top=100 right=100}
![](./img/t_ctla4.png)^[Created with BioRender.com]
:::
::: {.fragment fragment-index=7 .fade-in-then-out .absolute width="200" height="520" top=100 right=100}
![](./img/t_pd1.png)^[Created with BioRender.com]
:::

:::

:::

::::

## Immune checkpoint inhibitors (ICIs) 

::::{.columns}

:::{.column width="40%"}

:::{.fragment .fade-left}
* Monoclonal antibodies against:
  + CTLA4
  + PD-1
  + Programmed death-ligand 1 (PD-L1)
:::

:::{.fragment .fade-left}
:::{.fragment .semi-fade-out}
* Inhibitory signal
:::
:::

:::{.fragment .fade-left}
* Resulting in immune activation & ðŸ¤ž restoration of immune recognition of cancer
:::

:::

:::{.column width="60%"}

:::{.fragment .fade-right}
* Some ICIs include:
  + Ipilimumab (anti-CTLA4)
  + Pembrolizumab (anti-PD-1)
  + Nivolumab (anti-PD-1)
  + Durvalumab (anti-PD-L1)
  + Atezolizumab (anti-PD-L1)
:::

:::

::::

# Why is understanding primary resistance important?

## 
::: {.fragment fragment-index=1 .absolute width="729" height="186" top=10 left=10}
![](./img/nivo_melanoma.png)^[@robertNivolumabPreviouslyUntreated2015]
:::

::: {.fragment fragment-index=2 .absolute width="904" height="319" top=100 left=150}
![](./img/cm214.png)^[@albigesNivolumabIpilimumabSunitinib2020]
:::

::: {.fragment fragment-index=3 .absolute width="998" height="344" top=200 left=50}
![](./img/kn177.png)^[@andrePembrolizumabMicrosatelliteInstabilityHigh2020]
:::

::: {.fragment fragment-index=4 .absolute width="908" height="207" top=400 left=25}
![](./img/kn355.png)^[@cortesPembrolizumabChemotherapyAdvanced2022]
:::

::: {.fragment fragment-index=5 .absolute width="1611" height="338" top=200 left=-100}
![](./img/kn042.png)^[@mokPembrolizumabChemotherapyPreviously2019]
:::

##

![](./img/kn042_tps50.png){.animate__bounceInRight .animate__slow} ^[@decastroFiveYearOutcomesPembrolizumab2023]

::: {.fragment .fade-up}
**75** (25%) people receiving pembrolizumab died in the first 6 months vs **69** (23%) in control
:::

::: {.notes}
This is the overall survival for KN042, which is one of the main IO vs chemo trials in lung cancer. Note despite picking for TPS >= 50%, there is still a greater proportion of people dying in the pembrolizumab group in the first 6-ish months then those who had chemotherapy 
:::

## Neoadjuvant treatment
:::: {.columns}

::: {.column width="50%"}

::: {.fragment .fade-left}
* Neoadjuvant treatment = Cancer treatment prior to surgery
:::
::: {.fragment .fade-left}
* This can lead to:
  + Shrinkage of cancer {{< fa arrow-right >}} improved surgery
  + May be only opportunity to have systemic treatment
  + In some cancers, better survival
:::
::: {.fragment .fade-left}
* However, not **all** patients respond to treatment similar to in advanced disease.
:::

:::

::: {.column width="50%"}

::: {.fragment .fade-right}
![](./img/kn671.png)^[@wakeleePerioperativePembrolizumabEarlyStage2023]
:::

::: {.fragment .fade-right}
* **16** patients had progressive disease
:::

::: {.fragment .fade-right}
* Progression of disease = curable {{< fa arrow-right >}} **incurable**
:::

:::

::::

::: {.notes}
I will be focusing primarily on lung cancer as it is one of the cancers where immunotherapy is still used on its own as monotherapy and therefore allow for better understanding of the resistance mechanisms.
:::


# What is known about 1Â° resistance so far in lung cancer

## [Serine/threonine kinase 11 (STK11)/Liver kinase 1 (LKB1)]{style="font-size: 0.75em"}

::::{.columns}

:::{.column width="50%"}

:::{.fragment fragment-index=1 .fade-left}
* STK11/LKB1 is a serine/threonine kinase involved in:
  + Cellular energy signalling through AMP-activated protein kinase (AMPK) - particularly in stressful situations
  + Tumour suppressor - affects the mammalian target of rapamycin (mTOR) pathway
:::

:::{.fragment fragment-index=2 .fade-left}
* LKB1 germline mutation is most famous as the cause of Peutz-Jeghers syndrome 
:::

:::

:::{.column width="50%"}

:::{.fragment fragment-index=3 .fade-right}
+--------------------------------------------------------------------------------------------------------------+
| **Diagnostic criteria**                                                                                      |
+--------------------------------------------------------------------------------------------------------------+
| 2 or more histologically confirmed Peutz-Jeghers (PJ) polyps                                                 |
+--------------------------------------------------------------------------------------------------------------+
| Any number of PJ polyps in a person with a known family history of PJS in a close relative                   |
+--------------------------------------------------------------------------------------------------------------+
| Characteristic mucocutaneous pigmentation in an individual who has a family history of PJS in close relative |
+--------------------------------------------------------------------------------------------------------------+
| Any number of PJ polyps in an individual with the characteristic mucocutaneous pigmentation                  |
+--------------------------------------------------------------------------------------------------------------+
:::

:::

::::

## STK11/LKB1 in lung cancer

:::{.fragment fragment-index=1 .fade-left}
* STK11/LKB1 mutations are found in approximately 20% of lung cancers^[@debruijnAnalysisVisualizationLongitudinal2023]
:::

:::{.fragment fragment-index=3 .fade-left}
* STK11 has been found to be commonly co-mutated with KRAS mutations in lung cancer
:::

:::{.fragment fragment-index=4 .fade-left}
* In lung cancer samples and *in vivo* studies, KRAS mutations with STK11 loss {{< fa arrow-right >}} lower tumour infiltration of lymphocytes
:::

:::{.fragment fragment-index=4 .fade-left}
* Furthermore, clinical studies have shown that patients with STK11 mutations have worse survival outcomes^[@skoulidisSTK11LKB1Mutations2018; @malhotraClinicalOutcomesImmune2022]
:::

## STING

::::{.columns}

:::{.column width="50%"}

:::{.fragment fragment-index=1 .fade-left}
* cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is an important immune pathway in cells
:::

:::{.fragment fragment-index=3 .fade-left}
* The pathway leads to formation of pro-inflammatory cytokines after detecting cytosolic DNA
:::

:::{.fragment fragment-index=4 .fade-left}
* This is important in dealing with viral infections, but also in tumours, DNA damage {{< fa arrow-right >}} cytosolic DNA
:::

:::

:::{.column width="50%"}

:::{.fragment fragment-index=2 .fade-left .absolute width="540" height="360" top=150 right=-50}

![](./img/sting_pathway.png)^[Created with BioRender.com]

:::

:::

::::

## STK11 & STING 

![](./img/stk11_sting.png){.absolute width="350" top=100 left=400 .animate__fadeOut .animate__slow data-delay="30000"}^[Created with BioRender.com]

![](./img/stk11loss_sting.png){.absolute width="350" top=100 left=400 .animate__fadeIn .animate__slow data-delay="500"}

:::{.notes}
This is the presumed interaction between STK11/AMPK pathway and cGAS-STING pathways. The reduction in STK11 leads to reduction in AMPK. This leads to both direct and indirect downregulation of STING expression by methylation of the STING promoter by:
1. EZH2
2. DNMT1
The indirect pathway is due to reduction in S-adenosyl-methionine which is a main source of methyl group for DNMT1.
:::

## STING haplotypes

::: {.fragment .fade-left}
* It is recognised that there are single nucleotide polymorphisms (SNP) variants of STING in people with variable activity:
  + R71H, G230A, R293Q (most common variant)
  + R232H
:::

::: {.fragment .fade-left}
* The variants can lead to reduction in STING activity {{< fa arrow-right >}} reduced pro-inflammatory cytokines
  + This may have arisen as a protective mechanism in some populations against viral infections^[@suDNAinducedCGAMPEnhances2020]
    - In severe dengue, increased cytokines is a presumed mechanism for pathogenesis
:::

::: {.fragment .fade-left}
* However, does {{< fa arrow-down >}} activity {{< fa arrow-right >}} poor tumour immune response?
:::

## Other possible markers

:::{.fragment .fade-left}
* TCR repertoire (e.g. diverse epitopes)
:::

::: {.fragment .fade-left}
* Cytokine levels prior to starting treatment
:::

## Aims of project

:::{.fragment .fade-left}
* Investigate the impact of the STING pathway in immunotherapy resistance
:::

::: {.fragment .fade-left}
* Investigate STING haplotypes and their possible role in immune suppressive TME
:::

::: {.fragment .fade-left}
* Investigate other possible factors which may impact on immune suppressive TME
:::

## Acknowledgements
* Supervisors: Prof Tara Roberts & Prof Wei Chua for all of their time and advice
* Dr Alex James and Dr Yafeng Ma for all of their input - particularly around STING haplotypes

## References

::: {#refs}
:::

# Any questions?
